Anti-bacterial infection, inflammation, and leukemia composition and use thereof

Abstract

A method of inhibiting the growth of Gram-positive bacteria comprising administering an effective amount of Tellimagrandin II, its pharmaceutically acceptable salt, enantiomer, isomer or tautomer to a subject is provided. The Gram-positive bacteria comprise methicillin-resistant Staphylococcus aureus . A method of treating sepsis comprising administering an effective amount of Tellimagrandin II, its pharmaceutically acceptable salt, enantiomer, isomer or tautomer to a subject is also provided. A method of treating leukemia comprising administering an effective amount of Tellimagrandin II, its pharmaceutically acceptable salt, enantiomer, isomer or tautomer to a subject is further provided.

What is claimed is: 
     
       1. A method of inhibiting growth of Methicillin-resistant  Staphylococcus aureus  in a subject in need thereof comprising administering to the subject an effective amount of Tellimagrandin II together with an oxacillin or a doxycycline, wherein the Tellimagrandin II further comprises its pharmaceutically acceptable salt, enantiomer, isomer or tautomer. 
     
     
       2. The method of  claim 1 , wherein the Tellimagrandin II acts synergistically with the oxacillin or the doxycycline to inhibit the growth of Methicillin-resistant  Staphylococcus aureus.    
     
     
       3. The method of  claim 1 , wherein the Tellimagrandin II has a concentration of more than 30 μg/mL in vivo. 
     
     
       4. The method of  claim 2 , wherein the Tellimagrandin II and doxycycline act synergistically through an anti-oxidative mechanism. 
     
     
       5. The method of  claim 1 , wherein the oxacillin acts with Tellimagrandin II to reduce Penicillin-binding protein 2a expression in  Staphylococcus aureus.    
     
     
       6. The method of  claim 1 , wherein the oxacillin acts with the Tellimagrandin II to inhibit mecA gene expression in  Staphylococcus aureus.    
     
     
       7. The method of  claim 1 , wherein the Tellimagrandin II inhibits  Staphylococcus aureus  biofilm formation. 
     
     
       8. A method of treating leukemia in a subject in need thereof comprising administering to the subject an effective amount of Tellimagrandin II together with its pharmaceutically acceptable salt, enantiomer, isomer or tautomer. 
     
     
       9. The method of  claim 8 , wherein the Tellimagrandin II induces cell apoptosis and cell cycle arrest of leukemia cell. 
     
     
       10. The method of  claim 8 , wherein the Tellimagrandin II has a concentration in the range of 20-80 μM in vivo. 
     
     
       11. The method of  claim 9 , wherein the Tellimagrandin II induces cell apoptosis by increasing intracellular active oxygen species. 
     
     
       12. The method of  claim 9 , wherein the cell apoptosis of leukemia cell is induced by activating Caspase 3 and Caspase 7. 
     
     
       13. The method of  claim 9 , wherein the cell cycle arrest of leukemia cell is arrested in G2/M phase.